Building a robust pipeline to fight cancer

Our goal is to establish a sustainable clinical pipeline of novel and differentiated oncology programs geared towards achieving superior efficacy while minimizing the burden of side effects for patients. ADCs will continue to be the main pillar of VERAXA’s pipeline strategy. At the same time, our expertise and capabilities can be applied to other formats, and we aim to explore emerging synergies between existing and novel antibody modalities. With our expertise and capabilities, we develop novel antibody-based drug modalities for the treatment of cancer.

Current ADC and mAb developments

Program

Discovery

Preclinical

Phase I

Phase II

Indication

Partner

VX-A901 (mAb)

anti-FLT3

Hematological cancers

Proprietary

VX-A101 (ADC)

Solid tumors

Proprietary

VX-A001 (ADC)

Solid tumors

Proprietary

VX-A201 (ADC)

Lung cancer

Proprietary

VX-A901 - A novel therapeutic option for elderly AML patients

Acute myeloid leukemia (AML) is an aggressive cancer that mainly affects the elderly. Despite improvements, younger and fitter patients still tend to benefit more than older and less fit individuals. Treatment options for elderly patients and those who are not fit for intensive chemotherapy and stem cell transplantation are limited. The need for better therapies for older and unfit patients is growing.

FLT-3 is overexpressed in the majority of AML blasts

VX-A901 binds to primary blasts irrespective of mutation in FLT3
Optimized Fc-part induces ADCC via strong binding to NK cells

Distinct and complementary Mode of Action

VX-A901 can be combined with the first line of therapy
No ADCC effect on FLT-low expressing healthy bone marrow-derived HSPCs

Promising phase-1 clinical trial results

VX-A901 is safe and well tolerated in AML patients
Promising signs of monotherapy efficacy even in heavily pre-treated patients